NDA 217906 · Abbvie
Emblaveo
Avibactam Sodium, Aztreonam · Intravenous · Monobactam Antibacterial; beta Lactamase Inhibitor
Priority reviewLast checked: Nov 19, 2026Latest source record: Feb 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 7, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
64
17 Phase 3, 13 recruiting
FAERS reports
1
1 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 24, 2026.
EMBLAVEO is a combination of aztreonam, a monobactam antibacterial, and avibactam, a beta-lactamase inhibitor, that when used in combination with metronidazole, is indicated in patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI) including those caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens . Approval of this indication is based on limited clinical safety and efficacy data for EMBLAVEO. ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of EMBLAVEO and other antibacterial drugs, EMBLAVEO should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Intra-abdominal Infections EMBLAVEO, in combination with metronidazole, is indicated in patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI) including those caused by the following susceptible gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Klebsiella oxytoca , Enterobacter cloacae complex , Citrobacter freundii complex , and Serratia marcescens. Approval of this indication is based on limited clinical safety and efficacy data for EMBLAVEO [ see Clinical Studies ( 14.1 )] . 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of EMBLAVEO and other antibacterial drugs, EMBLAVEO should be used only to treat infections that are...
Mechanism: EMBLAVEO is an antibacterial drug [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EMBLAVEO · AVIBACTAM SODIUM EQ 0.5GM BASE/VIAL; AZTREONAM 1.5GM/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avibactam" as an intervention, any sponsor and status, largest first.
- A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe InfectionsPivotal-lookingNot yet recruiting
Southeast University, ChinaAcademic, hospital or other
NCT06939829 · 1,200 participants (planned) · Start May 1, 2025 · Primary completion Dec 31, 2027
Drug: treatment with CAZ-AVI · For: Patients With Critically Ill Infections
- A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial PneumoniaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01808092 · 969 participants · Start Apr 2013 · Primary completion Jan 2016
Drug: ceftazidim-avibactam (CAZ-AVI, experimental product); meropenem (active comparator) · For: Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP)
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Florida, Argentina · 123 sites in all
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAIPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06633718 · 786 participants (planned) · Start Oct 31, 2024 · Primary completion May 30, 2027
Drug: Meropenem and Pralurbactam; Saline and 2 more · For: Intra-abdominal Infections
Sites: Hangzhou, China
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01599806 · 641 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: Ceftazidime - Avibactam ( CAZ-AVI); Doripenem and 2 more · For: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Sites: Detroit, Michigan; St Louis, Missouri; Indiana, Pennsylvania · 57 sites in all
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsPivotal-lookingRecruiting
National University of SingaporeAcademic, hospital or other
NCT07004049 · 600 participants (planned) · Start Apr 21, 2025 · Primary completion Dec 31, 2028
Drug: Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline and 12 more · For: Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia and 2 more
Sites: Brisbane, Australia; Hangzhou, China; Xi'an, China · 41 sites in all
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01595438 · 598 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: Ceftazidime - Avibactam ( CAZ-AVI); Doripenem and 2 more · For: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Sites: Sylmar, California; Royal Oak, Michigan; Lima, Ohio · 80 sites in all
- A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaPivotal-lookingNot yet recruiting
Nanjing Yoko Biomedical Co., Ltd.Industry
NCT07634198 · 590 participants (planned) · Start Jun 4, 2026 · Primary completion Apr 1, 2028
Drug: YK-1169; Ceftazidime-avibactam Injection · For: Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)
- Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal InfectionsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01499290 · 493 participants · Start Mar 2012 · Primary completion Apr 2014
Drug: CAZ-AVI; Metronidazole and 1 more · For: Complicated Intra-Abdominal Infection
Sites: Chula Vista, California; San Diego, California; St Louis, Missouri · 56 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- apnoea1
- blood pressure decreased1
- chemical burn1
- pancreatic failure1
- renal failure1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, et al. · Lancet Infect Dis 2025 · Clinical Trial, Phase III, Comparative Study
- Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.
Xie R, Rogers H, Chow JW, et al. · Antimicrob Agents Chemother 2025 · Clinical Trial, Phase III, Multicenter Study
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.
Wang Y, Sholeh M, Yang L, et al. · Antimicrob Resist Infect Control 2025 · Systematic Review, Meta-Analysis
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.
Wagenlehner F, Caballero VR, Maheshwari V, et al. · J Comp Eff Res 2025 · Systematic Review, Network Meta-Analysis
- Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis.
Gupta N, Boodman C, Prayag P, et al. · Expert Rev Anti Infect Ther 2024 · Systematic Review, Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.